Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Merck opens first climate-neutral manufacturing facility in Ireland
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated
